AbCellera IPO Presentation Deck

OFFERING SUMMARY ISSUER (TICKER] BASE OFFERING SIZE OPTION TO PURCHASE ADDITIONAL SHARES PRICE RANGE GROSS PROCEEDS USE OF PROCEEDS BOOKRUNNERS EXPECTED PRICING DATE LOCK-UP PERIOD AbCellera Biologics Inc. (NASDAQ: ABCL) 23 million common shares (100% primary) 15% (100% primary) or 3.45 million common shares $14.00-$17.00 per share $356.5 million (assuming midpoint of pricing range and excluding option to purchase additional shares) The Company intends to use the net proceeds from this offering to: • Invest in research and development efforts towards deepening the technology and expertise along technology stack: • Invest in building business development team and marketing solutions to new and existing partners; and • General corporate purposes, including working capital, operating expenses and capital expenditures. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets AbCellera December 10, 2020 (post-market close) 180 days for the Company, directors, officers, and substantially all securityholders COPYRIGHT © ARCELLESA

View entire presentation